# Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease

> **NCT00304629** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 241 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** galantamine

## Key facts

- **NCT ID:** NCT00304629
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03
- **Primary completion:** —
- **Final completion:** 2002-03
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2011-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00304629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00304629, "Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00304629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*